Oragenics to Showcase Concussion Treatment at SCOPE Summit 2026
ByAinvest
Monday, Feb 2, 2026 8:31 am ET1min read
OGEN--
Oragenics will participate in SCOPE Summit 2026 to engage with global clinical research leaders ahead of its Phase 2a trial for concussion treatment. The company is developing intranasal therapeutics for neurological disorders, with its lead candidate ONP-002 advancing toward Phase 2a clinical trials in Australia. Oragenics is working to advance neurological care through its proprietary intranasal delivery platform.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet